Other
PT-141 (Bremelanotide)
A melanocortin receptor agonist approved by the FDA in 2019 as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women.
Also known as Bremelanotide · Vyleesi · PT141
At a glance
Dose summary
Reconstitution
What to draw, at the usual vial
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5.00 mg/mL. A typical 1.75 mg dose is 0.350 mL — pull the plunger to 35 units on a U-100 syringe.
Same dose, other vial sizes
| Vial | Water | Concentration | Draw | Units | Doses |
|---|---|---|---|---|---|
| 5 mg | 2 mL | 2.50 mg/mL | 0.700 mL | 70 units | 2 |
| 10 mg | 2 mL | 5.00 mg/mL | 0.350 mL | 35 units | 5 |
The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.
Mechanism & evidence
What it is, and what is known
A melanocortin receptor agonist approved by the FDA in 2019 as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. The label dose is 1.75 mg (1750 mcg) subcutaneously into the abdomen or thigh, taken AS NEEDED at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than 8 doses per month. Phase 2 dose-ranging also studied 0.75 and 1.25 mg, which is where the 750 mcg floor here comes from; nothing above the 1.75 mg label dose is supported.
IMPORTANT: this is not a scheduled compound. The scheduler stores it as 2x-week purely because that is the closest available slot to the label ceiling of 8 doses per month - do not read it as an instruction to dose on fixed days. Dose only before intended activity. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease, a flag this dataset has no field for, so check blood pressure before starting.
Efficacy in men is not established; use outside premenopausal women is off-label. The original intranasal formulation was abandoned in development after blood pressure increases, so the nasal route listed here reflects grey-market products, not an approved presentation.
The caveat
Approved only for acquired, generalised HSDD in premenopausal women. Efficacy in men is not established, and this is a dose-before-activity drug, not a scheduled one.Tolerability
Reported side effects
- Nausea, reported by roughly 40% of patients in the approval trials and the single most common reason for stopping
- Flushing (about 20%)
- Injection site reactions (about 13%)
- Headache (about 11%)
- Vomiting (about 5%)
- A transient rise in blood pressure of roughly 6/3 mmHg with a small fall in heart rate, peaking in the first hours and usually resolving within 12 hours
- Focal darkening of the skin, gums or face, reported in about 1% at label frequency and more likely with darker skin, daily dosing or more than 8 doses a month; it may not fully reverse after stopping
Hard stops
Do not use this if
- Pregnancy, possible pregnancy, or breastfeeding
- Under 18
These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.
Handling
Storage
Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.
References
Sources
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.